Approved January 1998
Noritate (metronidazole cream) 1% has been approved as a topical rosacea therapy for the treatment of inflammatory lesions and erythema (facial redness) associated with the condition.
Noritate has been shown to significantly reduce inflammatory lesions of rosacea in as little as four weeks with minimal skin dryness and irritation.
The Noritate drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.